The new drug treatment of domestic new crown pneumonia is the first in clinical application in Shenzhen Shenzhen

Text/Yangcheng Evening News all -media reporter Zhang Hua

Figure/Correspondent provided

Recently, the Eighth Hospital of the Affiliated City of Guangzhou Medical University officially introduced the new crown pneumonia therapy drug Anbaweicabi and Romi Siweizaba. It is reported that the drug is the latest antibody drug for the treatment of new crown pneumonia in my country. It is currently the first to be put into clinical use at the Third People's Hospital of Shenzhen Third People's Hospital and the Affiliated Hospital of Guangzhou Medical University.

Deng Xilong, director of the Eighth Hospital of Guangzhou Medical University Affiliated City, said in an interview that the combined therapy of these two drugs was passive immunity and was applied to high -risk people who could develop into severe illnesses. At present, the drug reserves are sufficient, and patients who need to use medicine can use medical insurance to pay medicines. Deng Xilong also mentioned that do not deified drugs, and they cannot completely prevent the infection of the new coronal virus.

Apply to high -risk people who may develop into severe illness

On July 7, Anbawei's combination therapy was listed in my country. At present, the Third People's Hospital of Shenzhen Third People's Hospital and the Eighth Hospital of the Affiliated City of Guangzhou Medical University, etc. It is understood that Anbawei's anti -anti -Romi Weishan anti -injection is a new crown virus developed by Tsinghua University, Shenzhen Third People's Hospital, and Tengsheng Huacuyin Pharmaceutical Technology (Beijing) Co., Ltd. drug.

The combination of Antimetabu and Romi Siwei Anti -Anti -Anti -Anti -Anti -Anti -Anti -Anti -therapy was approved by the State Drug Administration on December 8, 2021. It is used to treat light and ordinary types and is accompanied by progress (including hospitalization or death) high (including hospitalization or death) high New type of coronary virus infection with risk factor adults and adolescents (12-17 years old, weight ≥40kg). Among them, adolescents adapting to the witnesses are approved by the attachment. The combined therapy was approved by the National Health and Health Commission for approval of the "New Coronatte Virus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)" on March 15, 2022.

"Anbawei's anti -anti -Romi Sweet anti -injection is an antibody drug, which is a passive immune drug. In short, the patient basically has the resistance to the new crown pneumonia." Deng Xilong said that Deng Xilong said This drug is mainly used in high -risk groups with low immune function or may develop into severe illnesses, such as chronic obstructive pulmonary, severe cardiovascular and cerebrovascular diseases, or tumor patients who are receiving chemotherapy. These patients are either low resistance to viruses. Either it is easy to cause basic diseases after infection.

"It is worth noting that the use of these two drugs can not completely prevent infection, nor can it turn overcast as soon as the nucleic acid detection is used. Don't think that the virus is gone immediately, and there is no such divine medicine." Deng Xilong said.

The infusion drug can basically produce neutralized antibodies on the day

Talking about these two drugs on the market, Deng Xilong was quite pleased. She said that the listing of these two drugs is equivalent to the doctors' hands. "When we were popular in wild strains or Delta strains, we basically had no more clear effects of drugs. Now it is equivalent to drugs with clear curative effects. After strict clinical verification at home and abroad, these two types of drugs can significantly reduce the risk of patients' symptoms and develop into severe illness, thereby reducing the mortality rate. "

Deng Xilong said that the new crown virus has been mutated, and the drugs injected with antibodies are not "forever for all", and the virus may have immune escape. In the future, whether these healing drugs continue to be effective, it will continue to pay attention to clinically.

The injection vaccine is active immunity. New crown pneumonia antibody drugs are passive immunity. What is the difference between the two? Deng Xilong said that the new crown vaccine can produce antibodies after two weeks, and the neutralized antibody can last for half a year or more. However, the infusion of antibody drugs can basically produce neutralized antibodies on the same day, and the time to maintain the neutral antibody can also reach three months or even half a year.

It has been reported before that Anbawei's combination of combined therapy medicines is more expensive, about 10,000 yuan a needle. Can patients be affordable if they enter clinical use now? Deng Xilong said: "At present, this combined therapy drug has been included in medical insurance, and the medical expenses are paid by medical insurance."

It is understood that Anbaweicab and Romi Siwei Mipida have conducted clinical trials in the Eighth Hospital of the Municipal Hospital. "In 2021, the 8th phase of the clinical trial of the 8th Hospital of the Municipal Hospital used dozens of cases here. There are no obvious adverse reactions during the use of the drug. Some adverse reactions observed are basically acceptable. . "Deng Xilong said.

"Although there are new drugs for treating new crowns, personal protection cannot be relaxed." Deng Xilong said that whether it is imported or domestic treatment new crown drugs is effective, it is effective for reducing influence, but it cannot be said that it can be cleared as soon as the drug virus can be removed. Essence Therefore, non -drug prevention measures should not be relaxed, such as maintaining social distances, shaving hands, wearing masks, etc. are still effective.

- END -